BiotechTube

Focalin XR

Phase 3Completed
0 watching 0 views this week📈 Rising
77
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

ADHD

Conditions

ADHD

Trial Timeline

Jun 1, 2005 → Aug 1, 2005

NCT ID
NCT00141063

About Focalin XR

Focalin XR is a phase 3 stage product being developed by Novartis for ADHD. The current trial status is completed. This product is registered under clinical trial identifier NCT00141063. Target conditions include ADHD.

Hype Score Breakdown

Clinical
27
Activity
18
Company
10
Novelty
9
Community
10

Clinical Trials (2)

NCT IDPhaseStatus
NCT00141063Phase 3Completed
NCT00141050Phase 3Completed

Competing Products

20 competing products in ADHD

See all competitors
ProductCompanyStageHype Score
atomoxetineEli LillyApproved
85
Strattera (atomoxetine)Eli LillyApproved
85
Atomoxetine + placeboEli LillyApproved
85
Atomoxetine Hydrochloride + placeboEli LillyApproved
85
atomoxetine (Strattera)Eli LillyApproved
85
Atomoxetine + stimulants (any approved ADHD medication)Eli LillyPre-clinical
23
dasotraline + PlaceboSumitomo PharmaPhase 3
77
dasotralineSumitomo PharmaPhase 1
33
dasotraline 4mgSumitomo PharmaPhase 3
77
AZD1446 + AZD1446 + AZD1446 + PlaceboAstraZenecaPhase 2
52
Placebo + AZD3480 + AZD3480AstraZenecaPhase 2
52
MK0249 + Concerta (methylphenidate) + PlaceboMerckPhase 2
52
Dex-Methylphenidate hydrochloride Extended Release (Focalin® XR) + PlaceboNovartisApproved
85
Dexmethylphenidate HCl extended-release capsulesNovartisPhase 3
77
Methylphenidate hydrochlorideNovartisPhase 3
77
Focalin XRNovartisPhase 3
77
methylphenidate HCl ERCT + PlaceboPfizerApproved
84
methylphenidate HCl ERCTPfizerApproved
84
Very Low Dose Quillivant XR + Low Dose Quillivant XR + Moderate Dose Quillivant XRPfizerApproved
84
BrexpiprazoleLundbeckPhase 1
30

Other Products from Novartis

LCZ696Approved
85
zoledronic acidApproved
85
NateglinideApproved
85
TenofovirApproved
85
FTY720Approved
85